Hepaticojejunal stricture (HJS) is usually treated under percutaneous transhepatic or enteroscopic guidance [1, 2]. Percutaneous transhepatic biliary drainage (PTBD) confers several disadvantages such as external drainage and cosmetic issues. Although enteroscopy is an established procedure for patients with surgically altered anatomy, rates of technical success are not very high [3]. Endoscopic ultrasound-guided biliary drainage (EUS-BD) [4–7] has been traditionally indicated for failed endoscopic retrograde cholangiopancreatography (ERCP) in patients with unresectable malignant biliary obstruction. Expanding indications for EUS-BD have recently been reported such as EUS-guided antegrade stone removal [8–11]. However, the appropriate dilation technique for HJS remains controversial. Conversely, results from electrocautery dilation for stricture sites under ERCP guidance have been favorable [12], but conventional devices are associated with risk of bleeding due to burning [10]. A novel fine-gauge electrocautery dilator (ED) has recently become available in Japan [13]. The current study evaluated the safety and feasibility of transluminal antegrade dilation for hepaticojejunal stricture (HJS) using this novel ED.

**Patients and methods**

The Institutional Review Board at Osaka Medical College approved this retrospective study. Written informed consent was obtained from patients with HJS retrospectively enrolled between April 2018 and April 2019. Inclusion criteria comprised HJS with clinical symptoms such as obstructive jaundice or cholangitis.
Technical tips for transluminal antegrade dilation using novel ED

▶ Fig. 1 shows the novel Fine 025 fine-gauge ED (Medico’s Hirata, Osaka, Japan). The distal end of the outer dilator contains a metal tip, and the top of this metal tip is only 3 Fr. Shaft diameter for this electrocautery dilator is 7 Fr, and the shaft is strong and rigid to improve pushability. The electrocautery dilator is also wire-guided, coaxial with a 0.025-inch guidewire.

Technical tips for two-step transluminal antegrade dilation are as follows (▶Video 1). A GF-UCT260 echoendoscope (Olympus Optical, Tokyo, Japan) is inserted into the stomach, then the intrahepatic bile duct is identified and punctured using a Sono Tip Pro Control 19G needle (Medi-Globe GmbH, Rohrdorf, Germany). Bile juice is aspirated and contrast medium is injected (▶Fig. 2a) until an image of the HJS site is acquired. A stiff 0.025-inch VisiGlide guidewire (Olympus Medical Systems) is inserted into the biliary tract (▶Fig. 2b), then the intrahepatic bile duct wall and stomach wall are dilated using a 4-mm biliary dilation balloon catheter (REN, Kaneka Corp., Osaka, Japan) (▶Fig. 2c). If insertion of the stent delivery system remains challenging, additional dilation using a 6-mm balloon catheter or ED can be attempted. Finally, a fully-covered self-expandable metal stent (FCSEMS) (10 or 12 cm length, 10-mm diameter, Niti-S Biliary Covered Stent; Taewoong Medical, Seoul, South Korea) is deployed from the intrahepatic bile duct to the stomach (▶Fig. 2d).

The second step proceeds after 7 days, during which a fistula is created between the hepatic parenchyma and stomach wall. ▶Fig. 3 shows technical tips for antegrade dilation. The guidewire is passed beside the FCSEMS into the intrahepatic bile duct, then the FCSEMS is removed using biopsy forceps under duodenoscopic guidance (JF260V; Olympus Optical, Tokyo, Japan). A digital, single-operator SPY-DS cholangioscope (Boston Scientific Co., Marlborough, Massachusetts, United States) is inserted into the biliary tract through the fistula to evaluate the HJS site (▶Fig. 3a). If cholangioscopic findings are confirmed as benign [14] (▶Fig. 3b), antegrade dilation proceeds using the novel ED (▶Fig. 3c). A SPY-DS is also inserted into the HJS site to evaluate resolution of stricture and adverse events such as bleeding (▶Fig. 4a). These are also evaluated by cholangiography (▶Fig. 4b). A plastic Type IT stent (Gadelius Medical Co., Tokyo, Japan) is then deployed from the intrahepatic bile duct to the stomach (▶Fig. 4c).

Clinical follow-up and definition

Laboratory findings and symptoms such as tarry or bloody stools are evaluated at 1, 3, and 7 days after transluminal antegrade dilation to determine late bleeding from the HJS site. If no adverse events (AEs) are identified, the patient is discharged. Three months later, EUS-guided hepatocigastroscopy (HGS) stent exchange is attempted as follows. An ERCP catheter is inserted into the biliary tract upstream of the HJS site, and contrast medium is injected. If the medium flows from the biliary tract to the intestine across the HJS site, we consider that the HJS has been resolved, and an HGS stent is not deployed.

Additional intervention for HJS is considered if the flow of contrast medium is blocked.

The primary and secondary endpoints of this study were rates of technical success defined as functional antegrade HJS dilation using the novel ED and types of AEs, respectively. The follow-up period was from the time of antegrade HJS dilation using the novel ED to final clinical follow-up. Recurrent HJS was considered if clinical symptoms such as cholangitis or obstructive jaundice and bile duct dilation were evident on images. AEs were graded according to the criteria of the American Society for Gastrointestinal Endoscopy.

Results

During the study period, 22 patients showed HJS. Among them, six patients were treated using an enteroscopic approach due to absence of bile duct dilation or patient refusal to undergo EUS-HGS. Sixteen patients underwent EUS-HGS, and the procedure was successful in 15 patients (93.8%), indicating excellent technical outcomes. The reason for EUS-HGS failure was associated with guidewire manipulation, and the patient was treated via an enteroscopic approach. ▶Table 1 shows characteristics of the 15 patients (median age, 68 years; range, 60–78 years; male, n = 9). The primary surgery of HJS was cholangiocarcinoma (n = 5), intraductal papillary neoplasm (n = 7), or common bile duct stones (n = 3). The most prevalent clinical symptom was frequent cholangitis.

Cholangioscopy showed that the strictures were benign in all patients. Transluminal antegrade dilation using the novel ED was successful for all patients. In addition, no bleeding or perforation arose after HJS dilation in any patients according to cholangioscopic findings. The HJS site was evaluated again after about 90 days (median, 88 days; range, 82–101 days).
The contrast medium flowed from the intrahepatic bile duct to the intestine of in 14 of 15 patients (93.3%). The resolution rate of HJS was 92.9% (13 of 14 patients) at 6 months. Two patients with recurrent HJS underwent repeat EUS-HGS. The AE of mild cholangitis that developed in 1 patient was successfully treated by conservative management.

Discussion

Normally, HJS is treated by balloon dilation or plastic stent deployment under PTBD or enteroscopic guidance. Sato et al. evaluated clinical outcomes of double-balloon (DB) enteroscopy-assisted ERCP for HJS in 102 patients and identified predictors of long-term treatment success [14]. The technical success rate for treatment via DB-ERCP was 89.2% (91 of 102 patients) in that study, and the overall resolution rate of HJS was 76.9% (70 of 91 patients) during a median follow-up of 2.7 years. However, 22 of 53 patients (41.5%) who underwent initially successful balloon dilation for HJS experienced recurrence after a median of 3.4 months (range, 1–36.2) months. On the other hand, the rate of HJS recurrence was 10% (2 of 20 patients) with treatment by plastic stent deployment. According to that study, balloon dilation alone might be insufficient to treat HJS. Our resolution rate for HJS was 93.3% at 3 months. Although long-term results should be evaluated, the current findings in-
dicate that our technique might be more effective than balloon dilation or plastic stent deployment.

Tomoda et al compared balloon dilation alone with endoscopic stenting for treating HJS under enteroscopic guidance in 103 and 34 patients, respectively [15]. In this study, multivariate analysis selected only balloon dilation as an independent risk factor (hazard ratio, 2.86; 95% confidence interval, 1.44–6.55; \( P = 0.002 \)). Plastic stent deployment might thus be useful for treating HJS. However, although EUS-BD confers several advantages, such as a short procedural duration and a higher technical success rate than an enteroscopic approach, a plastic stent deployed at an HJS site might be difficult to remove via the EUS-HGS route. Various techniques through the HGS route, such as HJS stent removal and deployment, might thus sometimes prove challenging, and our technique applied to transluminal antegrade ED might offer a novel option for treating HJS.

Reported results for the ED technique are quite favorable [11, 12]. Gao et al. found that strictures in nine of 10 patients with refractory biliary and pancreatic duct stricture were successfully treated by ERCP using wire-guided needle-knife electrocautery [11]. Still, AEs of self-limited bleeds and biliary perforation developed. On the other hand, transpapillary dilation
of refractory severe biliary or main pancreatic duct strictures using a wire-guided coaxial diathermic dilator was successful in all 22 patients [12], with no severe AEs. However, we used the novel fine-gauge ED to reduce risk of bleeding that is still associated with ED due to burning. Cholangioscopic findings confirmed that AEs such as bleeding or perforation did not arise in any of our patients.

Our technique used a 10-mm-diameter FCSEMS. We believe that successful performance of EUS-HGS itself without stent migration or dislocation or bile leakage is extremely important in clinical practice. To prevent stent dislocation, a 10-mm-diameter FCSEMS was selected to resist the strong radial forces that may be encountered. In addition, this FCSEMS is removed after 1 week, so AEs associated with FCSEMS such as stent-induced ductal change may be avoided. Also, our technique may be a relatively complex procedure due to its two-step nature. However, after creation of the fistula between the intrahepatic bile duct and stomach, reintervention is easily and safely performed with a short procedure time compared with the enteroscopic approach.

Our study and technique have several limitations such as the small number of patients, high cost, short duration of follow-up, and retrospective nature of the study.

Conclusion

We concluded that transluminal antegrade ED is safe and feasible. Our technique might offer a new option with which to treat HJS, although a prospective study with long-term follow-up is needed.

Competing interests

The authors declare that they have no conflict of interest.

References

[1] Draganov P, Hoffman B, Marsh W et al. Long-term outcome in patients with benign biliary strictures treated endoscopically with multiple stents. Gastrointest Endosc 2002; 55: 680–686
[2] Mizukawa S, Tsutsumi K, Kato H et al. Endoscopic balloon dilatation for benign hepatojejunostomy anastomotic stricture using short double-balloon enteroscopy in patients with a prior Whipple’s procedure: a retrospective study. BMC Gastroenterology 2018; 18: 14
[3] Bukhari M, Kowalski T, Nieto J et al. An international, multicenter, comparative trial of EUS-guided gasrogastronomy-assisted ERCP versus enteroscopy-assisted ERCP in patients with Roux-en-Y gastric bypass anatomy. Gastrointest Endosc 2018; 88: 486–494
[4] Isayama H, Nakai Y, Itoi T et al. Clinical practice guidelines for safe performance of endoscopic ultrasound/ultrasonography-guided biliary drainage: 2018. J Hepatobiliary Pancreat Sci 2019; 26: 249–269
[5] Hedjoudj A, Sportes A, Grabar S et al. Outcomes of endoscopic ultrasound-guided biliary drainage: A systematic review and meta-analysis. United European Gastroenterol J 2019; 7: 52–59
[6] Guo J, Giovannini M, Sahai AV et al. A multi-institution consensus on how to perform EUS-guided biliary drainage for malignant biliary obstruction. Endosc Ultrasound 2018; 7: 356–365
[7] Itoi T, Sofuni A, Tsuchiya T et al. Endoscopic ultrasonography-guided transhepatic antegrade stone removal in patients with surgically altered anatomy: case series and technical review (with videos). J Hepatobiliary Pancreat Sci 2014; 21: E86–E93
[8] Kamiyama R, Ogura T, Okuda A et al. Electrohydraulic lithotripsy for difficult bile duct stones under endoscopic retrograde cholangiopancreatography and peroral transluminal cholangioscopy guidance. Gut Liver 2018; 15: 457–462
[9] Iwashita T, Nakai Y, Nara K et al. Endoscopic ultrasound-guided antegrade treatment of bile duct stone in patients with surgically altered anatomy: a multicenter retrospective cohort study. J Hepatobiliary Pancreat Sci 2016; 23: 227–233
[10] Honjo M, Itoi T, Tsuchiya T et al. Safety and efficacy of ultra-tapered mechanical dilator for EUS-guided hepatico-gastroscopy and pancreatic duct drainage compared with electrocautery dilator (with video). Endosc Ultrasound 2018; 7: 376–382
[11] Kawakami H, Kuriwati M, Kawakubo K et al. Transpapillary dilation of refractory severe biliary stricture or main pancreatic duct by using a wire-guided diathermic dilator (with video). Gastrointest Endosc 2014; 79: 338–343
[12] Gao D, Hu B, Pan YM et al. Feasibility of using wire-guided needle-knife electrocautery for refractory biliary and pancreatic strictures. Gastrointest Endosc 2013; 77: 752–758
[13] Ogura T, Nakai Y, Itoi T. Novel fine gauge electrocautery dilator for endoscopic ultrasound-guided hepatico-gastroscopy (with video). J Hepatobiliary Pancreat Sci 2019; 26: E3–E4
[14] Sato T, Kogura H, Nakai Y et al. Double-balloon endoscopy-assisted treatment of hepatojejunostomy anastomotic stricture and predictive factors for treatment success. Surg Endosc 2020; 34: 1612–1620
[15] Tomoda T, Kato H, Miyamoto K et al. Comparison between endoscopic biliary stenting combined with balloon dilation and balloon dilation alone for the treatment of benign hepatojejunostomy anastomotic stricture. J Gastrointest Surg 2019; doi:10.1007/s11605-019-04297-8 [Epub ahead of print]